Takeda reports Q1 revenue up 10.2%, keeps FY2026 outlook unchanged

Japanese drugmaker said core in-line brands offset much of the VYVANSE loss of exclusivity as it advanced launch plans for ORZEYFUL, rusfertide and zasocitinib.

25d ago